Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mavorixafor. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 known ✓ | P61073 | 20/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mavorixafor SCHEMBL29932203 | 1.00 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| Mavorixafor SCHEMBL4716578 | 1.00 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| Mavorixafor SCHEMBL1288182 | 1.00 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| Mavorixafor SCHEMBL2511950 | 1.00 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| Mavorixafor SCHEMBL29701264 | 1.00 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL2508418 | 0.99 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL2511014 | 0.99 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| Mavorixafor SCHEMBL3798687 | 0.99 | CXCR4 (0.98) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL14131151 | 0.97 | CXCR4 (0.95) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL30096707 | 0.97 | CXCR4 (0.95) | CXCR4CHRM2CYP2D6DRD2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 643 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| CN-112839649-B | CXCR4 inhibitor compositions and methods of making and using the same | X4 制药有限公司 | 2026-05-15 | — | — | CN | claimed |
| EP-4724096-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2026-04-15 | — | — | EP | claimed |
| EP-4724503-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCERS THROUGH INHIBITION OF CELL-IN-CELL PHENOMENON | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260069538-A1 | CXCR4 ANTAGONIST LOADED LIPOSOMES AND SILICASOMES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-03-12 | — | — | US | claimed |
| US-20260053790-A1 | TREATMENTS FOR CONDITIONS INVOLVING INCREASED IL-6 LEVELS | X4 PHARMACEUTICALS INC (US) | 2026-02-26 | — | — | US | claimed |
| US-12540165-B2 | HSP fusion protein with anti-chemorepellant agent for treatment of cancer | THE GENERAL HOSPITAL CORPORATION (US) | 2026-02-03 | — | — | US | claimed |
| US-20250360149-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR THERAPEUTICS INC (KR) | 2025-11-27 | — | — | US | claimed |
| US-20250360083-A1 | LIPID NANOPARTICLE FORMULATIONS AND METHODS OF USE THEREOF | UNIV NEBRASKA (US) | 2025-11-27 | — | — | US | claimed |
| US-20250361307-A1 | COMBINATION THERAPIES FOR TREATING HYPERPROLIFERATIVE DISORDERS | X4 PHARMACEUTICALS INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-3389652-B1 | METHODS FOR TREATING CANCER | X4 PHARMACEUTICALS INC (US) | 2022-09-28 | — | — | EP | claimed |
| EP-3393468-B1 | METHODS FOR TREATING IMMUNODEFICIENCY DISEASE | X4 PHARMACEUTICALS INC (US) | 2022-09-14 | — | — | EP | claimed |
| US-20220275032-A1 | HSP Fusion Protein with Anti-Chemorepellant Agent for Treatment of Cancer | THE GENERAL HOSPITAL CORPORATION | 2022-09-01 | — | — | US | claimed |
| US-20220257586-A1 | METHODS FOR TREATING IMMUNODEFICIENCY DISEASE | X4 PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | claimed |
| WO-2022113069-A9 | E PROTEIN CHANNEL BLOCKERS AND ORF3 INHIBITORS AS ANTI-COVID-19 AGENTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-07-28 | — | — | WO | claimed |
| US-20220184029-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROBLASTOMA | UNIV CHICAGO (US) | 2022-06-16 | — | — | US | claimed |
| US-11357742-B2 | Methods for treating cancer | X4 PHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | claimed |
| WO-2022113069-A1 | E PROTEIN CHANNEL BLOCKERS AND ORF3 INHIBITORS AS ANTI-COVID-19 AGENTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-06-02 | — | — | WO | claimed |
| US-11337969-B2 | Methods for treating cancer | X4 PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | claimed |
| US-11325951-B2 | HSP fusion protein with anti-chemorepellant agent for treatment of cancer | THE GENERAL HOSPITAL CORPORATION (US) | 2022-05-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11357742-B2 | Methods for treating cancer | FLT4, VHL, MKI67 | CXCR4 20/4885CHRM2 4802/4885CYP2D6 4798/4885 |
| US-20220257586-A1 | METHODS FOR TREATING IMMUNODEFICIENCY DISEASE | CXCR4, CXCL12, CCR5 | CXCR4 1/4885CHRM2 1717/4885CYP2D6 4161/4885 |
| US-20250360083-A1 | LIPID NANOPARTICLE FORMULATIONS AND METHODS OF USE THEREOF | CCR5, CXCR3, CCR1 | CXCR4 7/4885CHRM2 4875/4885CYP2D6 3404/4885 |
| US-11337969-B2 | Methods for treating cancer | CD274, PDCD1, PDCD1LG2 | CXCR4 17/4885CHRM2 4000/4885CYP2D6 4677/4885 |
| US-12540165-B2 | HSP fusion protein with anti-chemorepellant agent for treatment of cancer | HSP90AB2P, HSPA2, CDC37 | CXCR4 452/4885CHRM2 4291/4885CYP2D6 4284/4885 |
| US-20260069538-A1 | CXCR4 ANTAGONIST LOADED LIPOSOMES AND SILICASOMES | CXCL12, CXCR4, CXCR5 | CXCR4 2/4885CHRM2 1800/4885CYP2D6 4355/4885 |
| US-20260053790-A1 | TREATMENTS FOR CONDITIONS INVOLVING INCREASED IL-6 LEVELS | CXCR6, IL6, CCR6 | CXCR4 4/4885CHRM2 4268/4885CYP2D6 1768/4885 |
| US-20250361307-A1 | COMBINATION THERAPIES FOR TREATING HYPERPROLIFERATIVE DISORDERS | CXCR6, BCL6, CXCR4 | CXCR4 3/4885CHRM2 3991/4885CYP2D6 3052/4885 |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | BDKRB2, BDKRB1, HRH2 | CXCR4 1292/4885CHRM2 1132/4885CYP2D6 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.